You are here
Telithromycin Gains Indication To Treat Community-Acquired Respiratory Tract Infections
"Physicians, now more than ever, need a new therapeutic option to treat their patients suffering from mild to moderate RTIs, especially since approximately one-third of Streptococcus pneumoniae (the most common pathogen causing RTIs) are resistant to commonly used first line antibiotics," said Frank Douglas, MD, PhD, Executive Vice President and Chief Scientific Officer at Aventis.
"KETEK's innovative mechanism of action selectively targets common respiratory pathogens, including resistant strains, without significant effects on bacteria not normally involved in RTIs. This may be an important factor in minimizing the development of antibiotic resistance, a critical public health concern and one that I've seen in my clinical practice," added Paul Iannini, MD, Chairman, Department of Medicine, Danbury Hospital and Clinical Professor of Medicine, Yale University.
More than seven million patients have used KETEK since it was first introduced in major European, Latin American, and Asian markets. KETEK has been very well accepted by healthcare professionals and patients in Japan and France, the second and third largest antibiotic markets worldwide. The global market potential for KETEK is expected to exceed euro 1.5 billion.
In clinical trials, the most commonly reported side effects were nausea, headache, dizziness, vomiting, and diarrhea.